The VIP Advantage: Elevating Quality, Safety, and Performance in MedTech

Medtech companies strive to deliver the safest possible products to patients in the shortest time frames. Achieving these goals, however, isn’t easy. The Voluntary Improvement Program (VIP), supported by the FDA, is helping hundreds of facilities with these processes. Program members have seen fewer product recalls, faster closure of complaints, increased manufacturing capacity and the ability to provide life-saving treatments to many more high-risk patients.

In this guide, see how medtech companies are enhancing patient safety, optimizing business performance, reducing costs and improving quality through participation in the Voluntary Improvement Program.